GIM
AXSM icon

Glenmede Investment Management’s Axsome Therapeutics AXSM Stock Holding History

Glenmede Investment Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$878K Sell
7,232
-1,055
-13% -$119K ﹤0.01% 739
2025
Q2 		$865K Buy
+8,287
New +$877K ﹤0.01% 760

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Glenmede Investment Management's AXSM Position: Q3 2025 in Review

Glenmede Investment Management reduced its Axsome Therapeutics (AXSM) stake by 13% in Q3 2025, selling an estimated $119K and leaving 7,232 shares worth $878K. The position accounts for ﹤0.01% of the portfolio, ranked #739.

Glenmede Investment Management first reported a position in AXSM in Q2 2025 and has held it in 2 quarters since. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Glenmede Investment Management held 7,232 shares of Axsome Therapeutics worth $878K as of Q3 2025.
  • Glenmede Investment Management sold 1,055 Axsome Therapeutics shares in Q3 2025, an estimated $119K.
  • Axsome Therapeutics made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #739 holding.
  • Glenmede Investment Management first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.